nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—gallbladder cancer	0.566	1	CtDrD
Erlotinib—EGFR—gallbladder cancer	0.366	1	CbGaD
Erlotinib—ORM1—bile—gallbladder cancer	0.00339	0.145	CbGeAlD
Erlotinib—Vandetanib—ERBB3—gallbladder cancer	0.00164	0.354	CrCbGaD
Erlotinib—Gefitinib—ERBB3—gallbladder cancer	0.00156	0.336	CrCbGaD
Erlotinib—ORM1—gall bladder—gallbladder cancer	0.00094	0.0403	CbGeAlD
Erlotinib—NR1I2—liver—gallbladder cancer	0.000901	0.0387	CbGeAlD
Erlotinib—ALB—gall bladder—gallbladder cancer	0.000824	0.0354	CbGeAlD
Erlotinib—PIP4K2C—pancreas—gallbladder cancer	0.000807	0.0346	CbGeAlD
Erlotinib—Vandetanib—EGFR—gallbladder cancer	0.000737	0.159	CrCbGaD
Erlotinib—Gefitinib—EGFR—gallbladder cancer	0.0007	0.151	CrCbGaD
Erlotinib—LTK—lymph node—gallbladder cancer	0.000691	0.0297	CbGeAlD
Erlotinib—SLK—pancreas—gallbladder cancer	0.000687	0.0295	CbGeAlD
Erlotinib—TNK1—liver—gallbladder cancer	0.000662	0.0284	CbGeAlD
Erlotinib—AURKC—lymph node—gallbladder cancer	0.000597	0.0256	CbGeAlD
Erlotinib—FLT3—liver—gallbladder cancer	0.000568	0.0244	CbGeAlD
Erlotinib—JAK3—lymph node—gallbladder cancer	0.000553	0.0237	CbGeAlD
Erlotinib—ABL2—liver—gallbladder cancer	0.000543	0.0233	CbGeAlD
Erlotinib—EGFR—liver—gallbladder cancer	0.00053	0.0227	CbGeAlD
Erlotinib—PIP4K2C—liver—gallbladder cancer	0.000513	0.022	CbGeAlD
Erlotinib—TNK1—lymph node—gallbladder cancer	0.000507	0.0218	CbGeAlD
Erlotinib—ULK3—liver—gallbladder cancer	0.00049	0.021	CbGeAlD
Erlotinib—MKNK1—liver—gallbladder cancer	0.000461	0.0198	CbGeAlD
Erlotinib—SLK—liver—gallbladder cancer	0.000437	0.0188	CbGeAlD
Erlotinib—FLT3—lymph node—gallbladder cancer	0.000436	0.0187	CbGeAlD
Erlotinib—ABL2—lymph node—gallbladder cancer	0.000416	0.0179	CbGeAlD
Erlotinib—ABL1—pancreas—gallbladder cancer	0.000411	0.0177	CbGeAlD
Erlotinib—EGFR—lymph node—gallbladder cancer	0.000406	0.0174	CbGeAlD
Erlotinib—PIP4K2C—lymph node—gallbladder cancer	0.000394	0.0169	CbGeAlD
Erlotinib—STK10—liver—gallbladder cancer	0.00038	0.0163	CbGeAlD
Erlotinib—ULK3—lymph node—gallbladder cancer	0.000376	0.0161	CbGeAlD
Erlotinib—UGT1A1—liver—gallbladder cancer	0.000359	0.0154	CbGeAlD
Erlotinib—MKNK1—lymph node—gallbladder cancer	0.000354	0.0152	CbGeAlD
Erlotinib—MAP2K5—liver—gallbladder cancer	0.000339	0.0146	CbGeAlD
Erlotinib—SLK—lymph node—gallbladder cancer	0.000335	0.0144	CbGeAlD
Erlotinib—STK10—lymph node—gallbladder cancer	0.000291	0.0125	CbGeAlD
Erlotinib—CYP1A1—epithelium—gallbladder cancer	0.000277	0.0119	CbGeAlD
Erlotinib—ORM1—liver—gallbladder cancer	0.000276	0.0118	CbGeAlD
Erlotinib—SLCO2B1—liver—gallbladder cancer	0.000264	0.0113	CbGeAlD
Erlotinib—ABL1—liver—gallbladder cancer	0.000262	0.0112	CbGeAlD
Erlotinib—MAP2K5—lymph node—gallbladder cancer	0.00026	0.0112	CbGeAlD
Erlotinib—ALB—liver—gallbladder cancer	0.000242	0.0104	CbGeAlD
Erlotinib—CYP3A5—pancreas—gallbladder cancer	0.000241	0.0103	CbGeAlD
Erlotinib—CYP1B1—liver—gallbladder cancer	0.000222	0.00951	CbGeAlD
Erlotinib—ORM1—lymph node—gallbladder cancer	0.000211	0.00907	CbGeAlD
Erlotinib—SLCO2B1—lymph node—gallbladder cancer	0.000202	0.00869	CbGeAlD
Erlotinib—ABL1—lymph node—gallbladder cancer	0.000201	0.00861	CbGeAlD
Erlotinib—ALB—lymph node—gallbladder cancer	0.000185	0.00795	CbGeAlD
Erlotinib—CYP1B1—lymph node—gallbladder cancer	0.00017	0.0073	CbGeAlD
Erlotinib—CYP2C8—liver—gallbladder cancer	0.00017	0.00729	CbGeAlD
Erlotinib—ABCG2—liver—gallbladder cancer	0.000165	0.00709	CbGeAlD
Erlotinib—CYP1A2—liver—gallbladder cancer	0.000159	0.00682	CbGeAlD
Erlotinib—CYP1A1—liver—gallbladder cancer	0.000157	0.00673	CbGeAlD
Erlotinib—CYP3A5—liver—gallbladder cancer	0.000153	0.00658	CbGeAlD
Erlotinib—ABCB1—epithelium—gallbladder cancer	0.000144	0.00616	CbGeAlD
Erlotinib—ABCB1—pancreas—gallbladder cancer	0.000128	0.00549	CbGeAlD
Erlotinib—ABCG2—lymph node—gallbladder cancer	0.000127	0.00543	CbGeAlD
Erlotinib—CYP1A1—lymph node—gallbladder cancer	0.00012	0.00516	CbGeAlD
Erlotinib—CYP3A4—liver—gallbladder cancer	0.000115	0.00494	CbGeAlD
Erlotinib—CYP2D6—liver—gallbladder cancer	0.000113	0.00486	CbGeAlD
Erlotinib—ABCB1—liver—gallbladder cancer	8.14e-05	0.00349	CbGeAlD
Erlotinib—ABCB1—lymph node—gallbladder cancer	6.24e-05	0.00268	CbGeAlD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—HRAS—gallbladder cancer	4.45e-05	0.00112	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KEAP1—gallbladder cancer	4.44e-05	0.00112	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—KRAS—gallbladder cancer	4.37e-05	0.0011	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—EGFR—gallbladder cancer	4.37e-05	0.0011	CbGpPWpGaD
Erlotinib—MKNK1—Disease—ERBB3—gallbladder cancer	4.37e-05	0.0011	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—gallbladder cancer	4.34e-05	0.00109	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—ERBB2—gallbladder cancer	4.32e-05	0.00108	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—ERBB2—gallbladder cancer	4.32e-05	0.00108	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—ERBB2—gallbladder cancer	4.32e-05	0.00108	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—KRAS—gallbladder cancer	4.3e-05	0.00108	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—ERBB2—gallbladder cancer	4.28e-05	0.00107	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—ERBB2—gallbladder cancer	4.25e-05	0.00107	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—HRAS—gallbladder cancer	4.24e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—ERBB2—gallbladder cancer	4.23e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—BCL2—gallbladder cancer	4.2e-05	0.00105	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	4.19e-05	0.00105	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—NRAS—gallbladder cancer	4.17e-05	0.00105	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—HRAS—gallbladder cancer	4.15e-05	0.00104	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—HRAS—gallbladder cancer	4.15e-05	0.00104	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—KRAS—gallbladder cancer	4.13e-05	0.00104	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB4—gallbladder cancer	4.12e-05	0.00103	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—ERBB2—gallbladder cancer	4.08e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	4.07e-05	0.00102	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—NRAS—gallbladder cancer	4.04e-05	0.00101	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—ERBB2—gallbladder cancer	4e-05	0.001	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	3.98e-05	0.000999	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	3.97e-05	0.000996	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—NRAS—gallbladder cancer	3.94e-05	0.000989	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	3.89e-05	0.000977	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—ERBB2—gallbladder cancer	3.83e-05	0.00096	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	3.81e-05	0.000956	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—EGFR—gallbladder cancer	3.8e-05	0.000954	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KEAP1—gallbladder cancer	3.8e-05	0.000953	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—NRAS—gallbladder cancer	3.77e-05	0.000947	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—NRAS—gallbladder cancer	3.77e-05	0.000947	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—gallbladder cancer	3.76e-05	0.000944	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	3.76e-05	0.000943	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—HRAS—gallbladder cancer	3.72e-05	0.000933	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—NRAS—gallbladder cancer	3.71e-05	0.000932	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—EGFR—gallbladder cancer	3.68e-05	0.000924	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—HRAS—gallbladder cancer	3.65e-05	0.000916	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—gallbladder cancer	3.63e-05	0.000912	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB4—gallbladder cancer	3.63e-05	0.000909	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—KRAS—gallbladder cancer	3.59e-05	0.000901	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB3—gallbladder cancer	3.57e-05	0.000895	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	3.56e-05	0.000892	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	3.55e-05	0.00089	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	3.55e-05	0.00089	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—NRAS—gallbladder cancer	3.55e-05	0.00089	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB4—gallbladder cancer	3.54e-05	0.000887	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—NRAS—gallbladder cancer	3.53e-05	0.000885	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—NRAS—gallbladder cancer	3.51e-05	0.000881	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—HRAS—gallbladder cancer	3.51e-05	0.00088	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—NRAS—gallbladder cancer	3.5e-05	0.000877	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—KRAS—gallbladder cancer	3.48e-05	0.000873	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—gallbladder cancer	3.48e-05	0.000873	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	3.44e-05	0.000864	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—NRAS—gallbladder cancer	3.43e-05	0.00086	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—KRAS—gallbladder cancer	3.39e-05	0.000852	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	3.35e-05	0.000841	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	3.34e-05	0.000839	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	3.3e-05	0.000828	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—NRAS—gallbladder cancer	3.29e-05	0.000825	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—NRAS—gallbladder cancer	3.29e-05	0.000825	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	3.29e-05	0.000825	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—NRAS—gallbladder cancer	3.26e-05	0.000818	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—KRAS—gallbladder cancer	3.25e-05	0.000815	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—KRAS—gallbladder cancer	3.25e-05	0.000815	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—NRAS—gallbladder cancer	3.24e-05	0.000814	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—NRAS—gallbladder cancer	3.23e-05	0.00081	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—NRAS—gallbladder cancer	3.22e-05	0.000807	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	3.21e-05	0.000806	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—KRAS—gallbladder cancer	3.2e-05	0.000802	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—gallbladder cancer	3.19e-05	0.0008	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB3—gallbladder cancer	3.13e-05	0.000786	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—ERBB2—gallbladder cancer	3.12e-05	0.000782	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	3.12e-05	0.000782	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB4—gallbladder cancer	3.1e-05	0.000777	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB3—gallbladder cancer	3.06e-05	0.000767	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—HRAS—gallbladder cancer	3.05e-05	0.000766	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—KRAS—gallbladder cancer	3.05e-05	0.000766	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—NRAS—gallbladder cancer	3.04e-05	0.000763	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KRAS—gallbladder cancer	3.04e-05	0.000762	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	3.04e-05	0.000762	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—gallbladder cancer	3.03e-05	0.000761	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KRAS—gallbladder cancer	3.02e-05	0.000758	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	3.02e-05	0.000758	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KRAS—gallbladder cancer	3.01e-05	0.000755	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB4—gallbladder cancer	2.97e-05	0.000746	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	2.96e-05	0.000744	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—HRAS—gallbladder cancer	2.96e-05	0.000742	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—KRAS—gallbladder cancer	2.95e-05	0.00074	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—ERBB2—gallbladder cancer	2.94e-05	0.000739	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	2.91e-05	0.000731	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—HRAS—gallbladder cancer	2.89e-05	0.000724	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	2.86e-05	0.000717	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	2.85e-05	0.000715	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KRAS—gallbladder cancer	2.83e-05	0.00071	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	2.83e-05	0.00071	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KRAS—gallbladder cancer	2.83e-05	0.00071	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—gallbladder cancer	2.81e-05	0.000706	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KRAS—gallbladder cancer	2.8e-05	0.000704	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—KRAS—gallbladder cancer	2.79e-05	0.0007	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	2.78e-05	0.000697	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	2.77e-05	0.000695	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KRAS—gallbladder cancer	2.77e-05	0.000694	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	2.76e-05	0.000693	CbGpPWpGaD
Erlotinib—MKNK1—Disease—ERBB2—gallbladder cancer	2.74e-05	0.000687	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—HRAS—gallbladder cancer	2.72e-05	0.000682	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB3—gallbladder cancer	2.68e-05	0.000672	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB4—gallbladder cancer	2.67e-05	0.000669	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—ERBB2—gallbladder cancer	2.66e-05	0.000668	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	2.66e-05	0.000668	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—gallbladder cancer	2.62e-05	0.000658	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KRAS—gallbladder cancer	2.62e-05	0.000657	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—HRAS—gallbladder cancer	2.6e-05	0.000651	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—HRAS—gallbladder cancer	2.58e-05	0.000648	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	2.58e-05	0.000648	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB3—gallbladder cancer	2.57e-05	0.000645	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—HRAS—gallbladder cancer	2.57e-05	0.000645	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—HRAS—gallbladder cancer	2.56e-05	0.000641	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	2.52e-05	0.000632	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	2.51e-05	0.000629	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—gallbladder cancer	2.48e-05	0.000623	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—gallbladder cancer	2.42e-05	0.000608	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—HRAS—gallbladder cancer	2.41e-05	0.000603	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	2.41e-05	0.000603	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—HRAS—gallbladder cancer	2.41e-05	0.000603	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—HRAS—gallbladder cancer	2.38e-05	0.000598	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—HRAS—gallbladder cancer	2.37e-05	0.000595	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—NRAS—gallbladder cancer	2.37e-05	0.000595	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	2.37e-05	0.000594	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	2.36e-05	0.000593	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—HRAS—gallbladder cancer	2.35e-05	0.00059	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB3—gallbladder cancer	2.31e-05	0.000578	CbGpPWpGaD
Erlotinib—JAK3—Immune System—BCL2—gallbladder cancer	2.3e-05	0.000577	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—HRAS—gallbladder cancer	2.27e-05	0.00057	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NRAS—gallbladder cancer	2.24e-05	0.000562	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB2—gallbladder cancer	2.24e-05	0.000561	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—gallbladder cancer	2.23e-05	0.000558	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ERBB2—gallbladder cancer	2.23e-05	0.000558	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB4—gallbladder cancer	2.17e-05	0.000545	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—gallbladder cancer	2.16e-05	0.000542	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	2.13e-05	0.000534	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	2.11e-05	0.00053	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB4—gallbladder cancer	2.11e-05	0.00053	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NRAS—gallbladder cancer	2.08e-05	0.000522	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	2.06e-05	0.000517	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	2.05e-05	0.000515	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—KRAS—gallbladder cancer	2.04e-05	0.000512	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—gallbladder cancer	2.03e-05	0.000509	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—BCL2—gallbladder cancer	2.02e-05	0.000507	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB2—gallbladder cancer	1.97e-05	0.000493	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KRAS—gallbladder cancer	1.93e-05	0.000484	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB2—gallbladder cancer	1.92e-05	0.000481	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ERBB2—gallbladder cancer	1.9e-05	0.000477	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—gallbladder cancer	1.9e-05	0.000476	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB3—gallbladder cancer	1.88e-05	0.000471	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—gallbladder cancer	1.86e-05	0.000467	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB3—gallbladder cancer	1.83e-05	0.000458	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB4—gallbladder cancer	1.8e-05	0.000453	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KRAS—gallbladder cancer	1.79e-05	0.00045	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—KRAS—gallbladder cancer	1.74e-05	0.000438	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—gallbladder cancer	1.74e-05	0.000435	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—BCL2—gallbladder cancer	1.73e-05	0.000434	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—gallbladder cancer	1.7e-05	0.000427	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—gallbladder cancer	1.7e-05	0.000426	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—gallbladder cancer	1.69e-05	0.000425	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB2—gallbladder cancer	1.68e-05	0.000421	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB4—gallbladder cancer	1.67e-05	0.000418	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—gallbladder cancer	1.66e-05	0.000417	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—gallbladder cancer	1.64e-05	0.000411	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB2—gallbladder cancer	1.61e-05	0.000405	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—KRAS—gallbladder cancer	1.6e-05	0.000402	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB3—gallbladder cancer	1.56e-05	0.000391	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—gallbladder cancer	1.55e-05	0.000389	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—gallbladder cancer	1.54e-05	0.000387	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—gallbladder cancer	1.52e-05	0.000382	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—gallbladder cancer	1.5e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—gallbladder cancer	1.48e-05	0.000372	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KRAS—gallbladder cancer	1.46e-05	0.000367	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—gallbladder cancer	1.46e-05	0.000366	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—KRAS—gallbladder cancer	1.46e-05	0.000366	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—gallbladder cancer	1.45e-05	0.000363	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB2—gallbladder cancer	1.45e-05	0.000363	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB3—gallbladder cancer	1.44e-05	0.000361	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—gallbladder cancer	1.43e-05	0.000359	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	1.42e-05	0.000357	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—gallbladder cancer	1.36e-05	0.000342	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—gallbladder cancer	1.36e-05	0.000342	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	1.34e-05	0.000337	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—gallbladder cancer	1.33e-05	0.000333	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—gallbladder cancer	1.29e-05	0.000323	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—gallbladder cancer	1.28e-05	0.000321	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—gallbladder cancer	1.27e-05	0.000319	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—gallbladder cancer	1.26e-05	0.000315	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—gallbladder cancer	1.25e-05	0.000312	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—gallbladder cancer	1.24e-05	0.000312	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—gallbladder cancer	1.24e-05	0.000311	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—gallbladder cancer	1.23e-05	0.000308	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—gallbladder cancer	1.21e-05	0.000305	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	1.19e-05	0.0003	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—gallbladder cancer	1.18e-05	0.000296	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL2—gallbladder cancer	1.18e-05	0.000296	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB4—gallbladder cancer	1.17e-05	0.000293	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—gallbladder cancer	1.14e-05	0.000287	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—gallbladder cancer	1.12e-05	0.00028	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—gallbladder cancer	1.1e-05	0.000276	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—gallbladder cancer	1.1e-05	0.000276	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	1.09e-05	0.000274	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—gallbladder cancer	1.07e-05	0.000268	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—gallbladder cancer	1.06e-05	0.000265	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—gallbladder cancer	1.06e-05	0.000265	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB3—gallbladder cancer	1.01e-05	0.000253	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2—gallbladder cancer	1.01e-05	0.000253	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—gallbladder cancer	1e-05	0.000251	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—gallbladder cancer	9.78e-06	0.000245	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—gallbladder cancer	9.47e-06	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—gallbladder cancer	9.35e-06	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—gallbladder cancer	9.03e-06	0.000227	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—gallbladder cancer	8.98e-06	0.000225	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—gallbladder cancer	8.97e-06	0.000225	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—gallbladder cancer	8.71e-06	0.000218	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—gallbladder cancer	8.41e-06	0.000211	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—gallbladder cancer	8.18e-06	0.000205	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—gallbladder cancer	8.17e-06	0.000205	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—gallbladder cancer	8.14e-06	0.000204	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—gallbladder cancer	8.05e-06	0.000202	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—gallbladder cancer	7.93e-06	0.000199	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—gallbladder cancer	7.72e-06	0.000194	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—gallbladder cancer	7.5e-06	0.000188	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—gallbladder cancer	7.44e-06	0.000187	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—gallbladder cancer	7.04e-06	0.000177	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—gallbladder cancer	7.01e-06	0.000176	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—gallbladder cancer	6.87e-06	0.000172	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—gallbladder cancer	6.86e-06	0.000172	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—gallbladder cancer	6.56e-06	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—gallbladder cancer	6.4e-06	0.000161	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—gallbladder cancer	6.37e-06	0.00016	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—gallbladder cancer	6.32e-06	0.000159	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—gallbladder cancer	6.25e-06	0.000157	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—gallbladder cancer	5.98e-06	0.00015	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—gallbladder cancer	5.96e-06	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—gallbladder cancer	5.91e-06	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—gallbladder cancer	5.44e-06	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—gallbladder cancer	5.03e-06	0.000126	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—gallbladder cancer	4.81e-06	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—gallbladder cancer	4.14e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—gallbladder cancer	3.68e-06	9.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—gallbladder cancer	3.52e-06	8.83e-05	CbGpPWpGaD
